← Back to Search

Antiviral

ASC10 for COVID-19

Phase 1
Waitlist Available
Research Sponsored by Ascletis Pharmaceuticals Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from day 1 to study completion, up to 32 days
Awards & highlights

Study Summary

This trial will test a new drug to see if it is safe, effective and how it works in people with mild-moderate COVID-19.

Eligible Conditions
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day 1 to study completion, up to 32 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and from day 1 to study completion, up to 32 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Therapeutic procedure
PK parameters for ASC10, GLC01-700 (molnupiravir) and ASC10-A in plasma as AUC0-12h
Secondary outcome measures
Time (days) to sustained resolution of all targeted COVID-19 signs/symptoms

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ASC10Experimental Treatment1 Intervention
Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
Group II: PlaceboPlacebo Group1 Intervention
Participants will be randomized to receive placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ASC10
2022
Completed Phase 1
~80

Find a Location

Who is running the clinical trial?

Ascletis Pharmaceuticals Co., Ltd.Lead Sponsor
28 Previous Clinical Trials
2,593 Total Patients Enrolled
5 Trials studying COVID-19
171 Patients Enrolled for COVID-19

Media Library

ASC10 (Antiviral) Clinical Trial Eligibility Overview. Trial Name: NCT05596045 — Phase 1
COVID-19 Research Study Groups: Placebo, ASC10
COVID-19 Clinical Trial 2023: ASC10 Highlights & Side Effects. Trial Name: NCT05596045 — Phase 1
ASC10 (Antiviral) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05596045 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has ASC10 acquired clearance from the United States Food and Drug Administration?

"As ASC10 is in its initial trial phase, there is limited evidence of safety and efficacy so it has been assigned a rating of 1."

Answered by AI

Is this trial actively recruiting new participants?

"The clinical trial in question, which was posted on the 28th of November 2022 and updated lastly on the same date, is not accepting new participants. Despite this setback, 967 other medical studies are actively recruiting patients at this time."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients
2022. "Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05596045.
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top